Loading
MSH2 (DNA mismatch repair protein Msh2) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Endometrial cancer, Ovarian cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Component of the post-replicative DNA mismatch repair system (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. When bound, heterodimers bend the DNA helix and shields approximately 20 base pairs. MutS alpha recognises single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. MutS beta recognises larger insertion-deletion loops up to 13 nucleotides long. After mismatch binding, MutS alpha or beta forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. Location: Nucleus; Chromosome (UniProt). Locus 2p21-p16.3 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Prostate cancer | 0.2-3% | MSH2, MSH6, MLH1 or PMS2 inactivation, often by complex rearrangement | cBioPortal mutation in prostate_msk_2024: MSH2 26 of 2,260 (1.2%), MSH6 27 (1.2%), PMS2 17 (0.8%), MLH1 16 (0.7%); deep deletion adds MSH2 21, MSH6 15. In prad_su2c_2019: MSH2 6 of 444, MSH6 6, MLH1 3. MSH2 protein loss on immunohistochemistry was present in 14 of 1,176 primary adenocarcinomas and small-cell carcinomas, 1.2% (Guedes 2017). | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"MSH2" OR ABSTRACT:"MSH2" OR TITLE:"mutS homolog 2" OR ABSTRACT:"mutS homolog 2" OR TITLE:"DNA mismatch repair protein Msh2" OR ABSTRACT:"DNA mismatch repair protein Msh2" OR TITLE:"HNPCC" OR ABSTRACT:"HNPCC" OR TITLE:"HNPCC1" OR ABSTRACT:"HNPCC1" OR TITLE:"MSH-2" OR ABSTRACT:"MSH-2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MSH2, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/msh2.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/msh2.json. Licence CC BY-NC 4.0.